Mark Eisner, M.D., M.P.H., serves as Executive Vice President and Chief Medical Officer (CMO). Dr. Eisner is responsible for leading Translational and Clinical Development, including Clinical Research, Development Operations, Biometrics, Clinical Pharmacology, Pharmacovigilance, and Risk Management, as well as Medical Affairs and Regulatory Affairs. He has deep immunology and infectious disease expertise as well as clinical development experience. Dr. Eisner has an impressive track record of leading teams during times of strategically evolving portfolios.
Prior to joining Vir Biotechnology in June 2024, Dr. Eisner served as CMO at Sonoma Biotherapeutics, Inc. In this role, he led all development functions which included Biometrics, Regulatory, Clinical Science, Clinical Operations, Drug Safety and Pharmacology. Prior to this, Dr. Eisner served as CMO at FibroGen, where he led all development functions, which included being the Head of China Clinical Development and Clinical Operations. Prior to FibroGen, Dr. Eisner spent nearly 11 years at Genentech, holding positions of increasing responsibility, including Senior Vice President, Global Head of Product Development Immunology, Infectious Disease and Ophthalmology, and was accountable for late-stage clinical development of many products.
Dr. Eisner completed his A.B. degree in human biology at Stanford University and his M.D. degree at the University of Pennsylvania School of Medicine. He also holds an M.P.H. focusing on epidemiology from the University of California Berkeley, School of Public Health. He has an impressive list of publications and patents, honors and awards, and services for professional organizations.
What is Mark Eisner's net worth?
The estimated net worth of Mark Eisner is at least $819.16 thousand as of July 17th, 2025. Dr. Eisner owns 104,618 shares of Vir Biotechnology stock worth more than $819,159 as of February 19th. This net worth evaluation does not reflect any other investments that Dr. Eisner may own. Learn More about Mark Eisner's net worth.
How do I contact Mark Eisner?
Has Mark Eisner been buying or selling shares of Vir Biotechnology?
Mark Eisner has not been actively trading shares of Vir Biotechnology during the last quarter. Most recently, Mark Eisner sold 3,586 shares of the business's stock in a transaction on Thursday, July 17th. The shares were sold at an average price of $5.47, for a transaction totalling $19,615.42. Following the completion of the sale, the executive vice president now directly owns 104,618 shares of the company's stock, valued at $572,260.46. Learn More on Mark Eisner's trading history.
Who are Vir Biotechnology's active insiders?
Vir Biotechnology's insider roster includes Marianne De Backer (CEO & Director), Vanina de Verneuil (EVP, General Counsel and Corporate Secretary), Mark Eisner (Executive Vice President and Chief Medical Officer), Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Jason O'Byrne (Executive Vice President and Chief Financial Officer), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Brent Sabatini (CAO), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?
In the last twelve months, insiders at the sold shares 38 times. They sold a total of 3,243,863 shares worth more than $19,550,428.41. The most recent insider tranaction occured on February, 13th when CAO Brent Sabatini sold 1,530 shares worth more than $11,918.70. Insiders at Vir Biotechnology own 16.0% of the company.
Learn More about insider trades at Vir Biotechnology. Information on this page was last updated on 2/13/2026.
